NMO Spectrum Disorder Clinical Trial
Official title:
Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder
Verified date | May 2023 |
Source | First Affiliated Hospital of Guangxi Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: The pathogenesis of NMOSD has been linked to the cytokines interleukins (IL) -6, NOD-, LRR-and pyrin domain-containing 3 (NLRP3) and IL-18 that contribute to development of inflammatory reactionsmay. Although azathioprine (AZA) is efficacious in preventing NMOSD recurrence, it may have adverse effects (AEs) maybe related to the plasma concentrations. Objective: We would monitor the blood concentrations of AZA in NMOSD, and their relationship with cytokines, severity, efficacy, and safety range of the drug. Methods: A total of 53 NMOSD patients were included in the study, which included 20 patients who had received AZA treatment within 1 month, and 16 patients who had received AZA treatment within 6 months, as well as 17 patients who had received AZA treatment at least 12 months. The patient's immunotherapy regimen was low-dose hormone combined with AZA. AZA was started at small doses and added every two weeks after no AEs, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid. The following clinical data were collected: gender, age, clinical symptoms, EDSS score, number of recurrences and AEs, etc. Healthy controls (HC) comprised 10 individuals. AZA metabolite concentrations 6-thioguaninenucleotides (6-TGN) and 6-methylmercaptopurine nucleotides (6-MMPN) were measured by High-performance liquid chromatography (HPLC). Levels of IL-6, NLRP3 and IL-18 were measured by Enzyme-linked immunosorbent assay (ELISA).
Status | Completed |
Enrollment | 63 |
Est. completion date | April 1, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: All patients with NMOSD met the international consensus diagnostic criteria for NMOSD published in 2015. Before medication, TPMT activity was normal. Exclusion Criteria: Patients with fever, infection, or patients with other autoimmune diseases, uncontrolled malignancies, and other chronic diseases were excluded. |
Country | Name | City | State |
---|---|---|---|
China | Qingmeng Huang | Nanning | Guangxi |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital of Guangxi Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The concentrations of 6-TGN and 6-MMPN in NMOSD patients | The mean 6-TGN concentrations and 6-MMPN concentrations in 1 month after AZA treatment were tested by HPLC | 1 month | |
Primary | The concentrations of 6-TGN and 6-MMPN in NMOSD patients | The mean 6-TGN concentrations and 6-MMPN concentrations in 6 months after AZA treatment were tested by HPLC. | 6 months | |
Primary | The concentrations of 6-TGN and 6-MMPN in NMOSD patients | The mean 6-TGN concentrations and 6-MMPN concentrations in over 12 months after AZA treatment were tested by HPLC. | 12 months | |
Primary | Serum levels of IL-6, NLRP3 and IL-18 in NMOSD patients and HC | The levels of IL-6, IL-18, and NLRP 3 inflammasome were measured in the enzyme-linked immunoassay kit. | 1 month | |
Primary | Serum levels of IL-6, NLRP3 and IL-18 in NMOSD patients and HC | The levels of IL-6, IL-18, and NLRP 3 inflammasome were measured in the enzyme-linked immunoassay kit. | 6 months | |
Primary | Serum levels of IL-6, NLRP3 and IL-18 in NMOSD patients and HC | The levels of IL-6, IL-18, and NLRP 3 inflammasome were measured in the enzyme-linked immunoassay kit. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05154734 -
Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03829566 -
Autologous Transplant To End NMO Spectrum Disorder
|
Phase 2/Phase 3 | |
Recruiting |
NCT05403138 -
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
|
Phase 2/Phase 3 | |
Completed |
NCT05432713 -
A Study of LP-168 in Healthy Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT04822623 -
Imaging Evaluation of Central Nervous Autoimmune Diseases
|
||
Completed |
NCT04227470 -
A Study of HBM9161 in NMOSD Patients
|
Phase 1 | |
Not yet recruiting |
NCT06280755 -
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
|
||
Recruiting |
NCT05414890 -
Sensitivity and Specificity of TSA-CBA for Autoantibodies Against Neural Antigen Determination
|
||
Recruiting |
NCT05840055 -
ACT With NMOSD Patients and Caregivers Pilot Study
|
N/A | |
Recruiting |
NCT05004493 -
Biorepository and Registry for Plasma Exchange Patients
|
||
Recruiting |
NCT04106830 -
Clinical and Imaging Patterns of Neuroinflammation Diseases in China (CLUE)
|
||
Completed |
NCT03766347 -
Pediatric NMOSD Observational Study
|
||
Recruiting |
NCT05154370 -
China National Registry of Neuro-Inflammatory Diseases
|
||
Recruiting |
NCT06443333 -
National, Multicentric Registry Study on Neuroimmunological Diseases in China
|
||
Recruiting |
NCT05145361 -
Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
|
Early Phase 1 | |
Not yet recruiting |
NCT05974293 -
A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders
|
Phase 2 | |
Completed |
NCT04355611 -
Epidemiological Characteristics of COVID-19 in Patients With MS or NMO
|
||
Recruiting |
NCT05792462 -
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
|
Phase 1/Phase 2 |